GPT and cancer: Of note, with the frequency of CDKN2A ALT extracted from the MSK-MetTropism cohort, we found a significant correlation between CDKN2A ALT frequency and ORRs (r, 0.58; P = 0.002; Figure S1I), suggesting that cancer patients with CDKN2A ALT might benefit more from immunotherapy.